Lazard Asset Management LLC Omeros Corp Transaction History

Lazard Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.75 - $3.96 $54,206 - $122,661	-30,975 Reduced 87.84%	4,286 $9,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $7.46 $11,711 - $28,273	3,790 Added 12.04%	35,261 $111,000
Q2 2022 Aug 09, 2022	SELL	$1.92 - $6.28 $22,504 - $73,607	-11,721 Reduced 27.14%	31,471 $86,000
Q1 2022 May 13, 2022	BUY	$5.07 - $7.2 $21,730 - $30,859	4,286 Added 11.02%	43,192 $259,000
Q4 2021 Feb 09, 2022	BUY	$5.67 - $8.54 $220,597 - $332,257	38,906 New	38,906 $250,000
Q3 2021 Nov 15, 2021	SELL	$13.4 - $16.3 $343,093 - $417,345	-25,604 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$14.81 - $19.13 $316,741 - $409,133	-21,387 Reduced 45.51%	25,604 $379,000
Q1 2021 May 14, 2021	SELL	$14.52 - $23.53 $197,181 - $319,537	-13,580 Reduced 22.42%	46,991 $836,000
Q4 2020 Feb 11, 2021	BUY	$10.14 - $15.19 $614,189 - $920,073	60,571 New	60,571 $865,000
Q3 2020 Nov 13, 2020	SELL	$9.57 - $21.32 $1.45 Million - $3.23 Million	-151,430 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$12.21 - $16.99 $1.85 Million - $2.57 Million	151,430 New	151,430 $2.23 Million

120

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $684M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.